{"schema_version":"secwatch.filing_event.v1","accession":"0001538210-22-000028","form_type":"8-K","ticker":null,"cik":"0001538210","company_name":"NexImmune, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.075759+00:00","generated_at":"2026-06-21T20:04:21.996522+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NexImmune pivots to AIM INJ platform, cuts workforce 30%, pauses two cell therapy trials","bullets":["Strategic shift: focus on AIM INJ 'off-the-shelf' platform; pause NEXI-001 AML and NEXI-003 HPV trials, seek external partners.","Workforce reduction from 74 to ~50 employees; approx $0.7M severance costs expected in Q4 2022.","Cash $45.9M as of Sep 30, 2022 (down from $53.1M June 30); cash runway extended to Q3 2023 via restructuring.","Q3 2022 net loss $14.7M ($0.60 loss per share) vs $14.6M ($0.65) prior year; R&D $11.1M, G&A $3.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001538210-22-000028","json":"https://secwatch.observer/filing/0001538210-22-000028.json","markdown":"https://secwatch.observer/filing/0001538210-22-000028.md","text":"https://secwatch.observer/filing/0001538210-22-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1538210/000153821022000028/0001538210-22-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1538210/000153821022000028/nexi-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:04:21.996522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f8cf8fe47395c14234cc2e6746789433725c6d43","claim":"NexImmune, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss, according to generally accepted accounting principles in the U.S. GAAP, was $14.7 million for the quarter, or, EPS $0.60.","evidence_excerpt":"Net loss, according to generally accepted accounting principles in the U.S. GAAP, was $14.7 million for the quarter, or a basic and diluted GAAP loss per share of $0.60.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000153821022000028/0001538210-22-000028-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss, according to generally accepted accounting principles in the U.S. GAAP, was $14.7 million for the quarter, or"},{"label":"EPS","value":"$0.60"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"72df9823c6039aae001dbc10e9ebcc90e117d48b","claim":"NexImmune, Inc. announced a restructuring with charges of approximately $0.7 million affecting Company (reduce the Company’s workforce from 74 full-time employees as of September 30, 2022 to approximately 50 full-time employ).","evidence_excerpt":"On November 14, 2022 , NexImmune, Inc. (the “Company”) announced that, following a strategic review of its pipeline, indications, timelines and cash position, its Board of Directors approved and its management is implementing a strategic realignment initiative and corresponding reduction in workforce, designed to reduce costs and reallocate resources towards its preclinical development programs based on its proprietary Artificial Immune Modulation, or AIM TM , technology. The realignment would reduce the Company’s workforce from 74 full-time employees as of September 30, 2022 to approximately 50 full-time employees. The Company estimates that it will incur approximately $0.7 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000153821022000028/0001538210-22-000028-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.7 million"},{"label":"Affected area","value":"Company"},{"label":"Headcount","value":"reduce the Company’s workforce from 74 full-time employees as of September 30, 2022 to approximately 50 full-time employ"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}